Treatment with lenvatinib and pembrolizumab has shown promise in patients with metastatic clear cell renal cell carcinoma who have already received an immune checkpoint inhibitor.
Massachusetts General Hospital’s Severe Immunotherapy Complications Service focuses on the increasing number of "rare" cases of immunotherapy-related adverse events.
